# Health-related quality of life in adolescent and young adult cancer survivors

# Erika Harju<sup>1</sup> - Katharina Roser<sup>1</sup> - Silvia Dehler <sup>2,3</sup> - Gisela Michel<sup>1,4\*</sup>

#### **ABSTRACT**

Purpose Today survival rates for adolescent and young adult (AYA) cancer patients exceed 80%. However, cancer and treatment leave many patients suffering from chronic conditions. These late effects may impair their health-related quality of life (HRQoL). We aimed to (1) compare HRQoL of AYA cancer survivors with the Swiss general population and (2) investigate socio-demographic and cancer-related characteristics associated with poor HRQoL.

Methods AYA cancer survivors (age 16-25 at diagnosis; ≥5 years survival) who had been identified through the Cancer Registry Zurich and Zug, Switzerland filled out a questionnaire. We assessed HRQoL using the Short-Form 12 (SF-12), producing two scores: Physical Component Summary score (PCS, physical health) and Mental Component Summary score (MCS, mental health). We used multivariable logistic regression analyses to investigate associated characteristics.

\*Gisela Michel gisela.michel@unilu.ch

## Citation:

Harju E, Roser K, Dehler S, Michel G (2018) Health-related quality of life in adolescent and young adult cancer survivors. *Support Care Cancer*. 26(9), 3099-3110. doi:10.1007/s00520-018-4151-z

https://link.springer.com/article/10.1007%2Fs00520-018-4151-z

Results We compared 155 survivors with 350 controls. Survivors had significantly lower physical health than controls (mean=52.5 vs. mean=54.7, p < 0.001). Male survivors reported better mental health than controls (55.2 vs.53.3, p=0.078) and females slightly worse (49.8 vs.51.8, p=0.285). Poor physical health was strongly associated with having a migration background (OR=4.63, p=0.008) and unemployment (OR=7.66, p=0.005). Poor mental health was associated with female sex (OR=2.69, p=0.057), suffering from late effects (OR=5.91, p<0.001) and a migration background (OR=5.82, p=0.004).

Conclusions Results emphasize the need for individualized support services to improve survivors' HRQoL in vulnerable subgroups. We recommend adapted care for women and migrants, in addition to educational and employment support systems.

*Keywords* Adolescent, Young adult; Cancer; Survivor; SF-12; Health-related quality of life

#### INTRODUCTION

With increasing survival rates of adolescent and young adult (AYA) cancer in Europe, exceeding 80% today [1,2], the question on the quality of survival in this growing population arises. This population of AYA cancer survivors encounters a high risk for adverse late outcomes (late effects) [3], including second malignancies, cardiovascular and pulmonary conditions, endocrine dysfunction, neurological disorders, infertility, as well as psychological and social problems [4-7,3]. More than 60% of survivors report having at least one chronic condition and over one third of them report having at least two [6].

AYAs find themselves in a challenging state of development between childhood and adulthood. A diagnosis of cancer might interfere with these developmental milestones and thus have an important impact on their health related quality of life (HRQoL). Later on, the presence of late effects may further affect their HRQoL

HRQoL is a complex construct mainly defined by an individual's perception of his or her physical and mental health over time [8,9]. HRQoL has been widely studied in childhood cancer survivors [10-13], whereas AYA cancer

<sup>&</sup>lt;sup>1</sup> Department of Health Sciences and Health Policy, University of Lucerne, Frohburgstrasse 3, 6002 Lucerne, Switzerland

<sup>&</sup>lt;sup>2</sup> Cancer Registry Zurich and Zug, Institute of Surgical Pathology, University Hospital Zurich and Epidemiology, Biostatistics and Prevention Institute, University Zurich, Vogelsangstrasse 10, 8091 Zurich, Switzerland,

<sup>&</sup>lt;sup>3</sup> Departement Gesundheit und Soziales, Abteilung Gesundheit, Bachstrasse 15, 5001 Aarau, Switzerland

<sup>&</sup>lt;sup>4</sup> Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland

survivors' HRQoL has only recently come to the focus of attention [14-16,7]. In some studies with childhood cancer survivors, findings suggest that survivors' HRQoL is comparable to the norm population [10,11,13], while another study found survivors reporting significantly poorer HRQoL [12]. Cancer relapse and chronic problems have been strongly associated with poorer HRQoL in the areas well-being and physical health [10,12]. Despite experiencing impairments, childhood cancer survivors also demonstrate resilience and higher psychological well-being than their peers [11,13].

AYAs have emerged as a unique group in the clinical setting that requires specialized and cautious care and practice guidelines when facing the specific challenge of cancer diagnosis [17,18]. The previously limited amount of studies on AYAs has recently been increasing, examining not only their HRQoL and health behaviors, but also psychosocial outcomes [19,20]. HRQoL in AYAs has already been studied in Germany [21], the United Kingdom [22] and the United States [23]. However, to address quality of survivorship internationally, it is essential to expand the scope of countries reporting on survivors' quality of life. Therefore, we aimed to (1) compare HRQoL of AYA cancer survivors to the Swiss general population, and (2) investigate socio-demographic and cancer-related characteristics associated with poor HRQoL

# **METHODS**

## Sample and procedure

We identified eligible AYA cancer survivors in the population-based Cancer Registry Zurich and Zug. Participants were eligible for our study if they were diagnosed between January 1990 and December 2005 at age 16 to 25 years, and survived ≥5 years. To allow for a comparison with an associated study including childhood cancer survivors the sample was limited to the following diagnoses: central nervous system (CNS) tumors, germ cell tumors, lymphomas, leukemias, neuroblastomas, renal, hepatic, and bone tumors, as well as soft tissue sarcomas [24]. The Cancer Registry Zurich and Zug provided addresses of all eligible survivors. If necessary the addresses were updated using web search and by contacting the community where the survivors had resided last.

Eligible survivors received a cover letter, study information, informed consent form, questionnaire, and prepaid return envelope. Four weeks later, non-responders received another copy of the questionnaire. Data collection took place between August 2010 and January 2012.

The control group consisted of a subgroup of a random sample of the Swiss general population, who participated in a study on health and well-being in Switzerland. Eligible participants of this study were 18-75 years of age and resident in Switzerland. Their information was collected between 2015 and 2016. For direct comparison only those in the same age-group (20-47 years) as the AYA cancer survivors were included in the analyses.

The study was approved by the Cantonal Ethics Committee of Zurich (Ref No. EK: 2010-0228/2), and participants gave informed consent.

#### Measurements

The questionnaire assessed information on attendance and preferences for the organization of follow-up care, quality of life, and psychological distress.

Outcome health-related quality of life

HRQoL was assessed by the SF-12 [25]. The SF-12 questionnaire has been developed to provide a shorter but valid alternative to the SF-36 and is a good and useful instrument successfully used across different countries to assess HRQoL in both healthy and chronically ill populations [26-29]. The SF-12 questionnaire uses weighted subscales to produce two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Raw scores were converted into T-scores (mean=50, SD=10) according to age- and sex-stratified norm data from the Socio Economic Panel study standardized German population norm [27,25]. Higher scores indicate better HRQoL. The control group completed the SF-36 and we used the respective twelve items from the SF-12 to calculate their SF-12 scores.

With health status and health perception being age dependent, PCS and MCS tend to vary over life span. Therefore age-specific means indicate the average health for a specific age group. An individual's HRQoL can be best interpreted when knowing whether that person's score is above or below average. Therefore cut-off points for individual scores have been established using statistical methods [30]. Having a score that is below the cut-off indicates that this person has significantly worse HRQoL than his or her comparison group. The PCS difference score for poor health was defined as 6.97 points below the age-specific group mean (i.e. PCS≤45.5), and the MCS difference score for poor mental health as 6.24 points below the mean (i.e. MCS <47.5) [30]. We thus created binary variables indicating poor physical health when PCS  $\leq$  45.5, and poor mental health when MCS  $\leq$  47.5, respectively.

#### Socio-demographic characteristics

We assessed sex, age and educational achievement (compulsory education: up to ninth grade; vocational education: vocational training/apprenticeship, high school degree, or teacher's college; upper secondary education: college and university of applied science; university degree [31,32]. In the university education category no one reported having poor physical or poor mental health. Therefore we combined upper secondary education and university degree. Further we assessed employment (employed/unemployed), relationship status (survivors were asked whether they had a partner or not: (yes/no)), and migration background (yes/no). The definition of migration background was adapted from the Swiss Federal Statistical Office's definition [33]: Not being Swiss citizen, or not Swiss citizen since birth, or not born in Switzerland, was coded as having a migration background.

#### Cancer-related characteristics

Participants were asked whether they were suffering from *late effects* of the former cancer diagnosis or treatment (yes/no) and had the possibility to specify them. Further, we asked whether they had been diagnosed with a *relapse* (yes/no), or a *second malignancy* (yes/no).

The Cancer Registry Zurich and Zug provided information on *diagnosis* (classified according to the International Classification of Childhood Cancer, third edition) [34]. For the regression analyses we grouped diagnoses into six major groups: lymphoma, germ cell tumor, sarcoma, leukemia, CNS tumor, and other, following the ranking of the most common cancers in our study population and the AYA cancer population in general [17,35,1]. Furthermore the registry provided information on survivors' age at diagnosis (16-20 years; 21-25 years); time since diagnosis (5-10 years; 11-15 years; 16+ years), and *treatment* (surgery only; chemotherapy: may have had surgery but not radiotherapy; radiotherapy: may have had surgery and/or chemotherapy).

#### Statistical analysis

For the comparison between participants and non-participants we used descriptive statistics and chi-square tests for proportions. To account for differences between survivors and controls for aim 1 we standardized the controls on sex, age at study and migration background according to the marginal distribution of the survivors. The mean PCS and MCS scores were compared using t-tests (significance threshold p≤0.05). For proportion comparison of poor physical and poor mental health between survivors and controls we used adjusted Wald chi-square tests (significance threshold: p≤0.05). For aim 2 (to investigate demographic and clinical characteristics associated with

poor HRQoL), we ran univariable and multivariable logistic regression. Only characteristics associated at p $\leq$ 0.10 in the univariable logistic regression were included in the multivariable logistic regression. Likelihood ratio tests delivered global *p*-values for the multivariable logistic regression (significance threshold: p $\leq$ 0.1). All analyses were performed using Stata version 14.2 (StataCorp, College Station, TX, USA).

**Table 1:** Study population characteristics, comparing participants, non-par-

ticipants and a sample of the general population

|  | General    |            | • •      |            | Non-     |            |                      |
|--|------------|------------|----------|------------|----------|------------|----------------------|
|  | populati   | on         | Partici  | pants      | partici  | pants      |                      |
|  | N          | %          | N        | %          | N        | %          | p-value <sup>a</sup> |
| Total  | 350        | 100        | 155      | 100        | 309      | 100        |                      |
| Sociodemographic characteristics             |            |            |          |            |          |            |                      |
| Sex <sup>b</sup>                             |            |            |          |            |          |            | 0.151                |
| Female                                       | 210        | 40.0       | 59       | 38.1       | 96       | 31.0       |                      |
| Male   | 140        | 60.0       | 96       | 61.9       | 210      | 68.0       |                      |
| Age at study (years)                         |            |            |          |            |          |            | 0.548                |
| 20-29  | 91         | 26.0       | 42       | 27.1       | 74       | 24.0       |                      |
| 30-39  | 153        | 43.7       | 82       | 52.9       | 180      | 58.2       |                      |
| 40+  | 106        | 30.3       | 31       | 20.0       | 55       | 17.8       |                      |
| Migration Background No migration background | 275        | 78.6       | 122      | 78.7       | n/a      | n/a        |                      |
| Migration<br>background                      | 75         | 21.4       | 33       | 21.3       | n/a      | n/a        |                      |
| Partnership <sup>b</sup>                     |            |            |          |            |          |            |                      |
| No partner                                   | 66         | 18.9       | 35       | 22.6       | n/a      | n/a        |                      |
| Partnership                                  | 272        | 77.7       | 120      | 77.4       | n/a      | n/a        |                      |
| Education <sup>b</sup>                       |            |            |          |            |          |            |                      |
| Compulsory education                         | 10         | 2.9        | 12       | 7.7        | n/a      | n/a        |                      |
| Vocational training                          | 150        | 42.9       | 73       | 47.1       | n/a      | n/a        |                      |
| Upper<br>Secondary<br>education              | 58         | 16.6       | 50       | 32.3       | n/a      | n/a        |                      |
| University education                         | 114        | 32.6       | 19       | 12.3       | n/a      | n/a        |                      |
| Employment <sup>b</sup>                      |            |            |          |            |          |            |                      |
| Not employed                                 | 37         | 11.0       | 14       | 9.0        | n/a      | n/a        |                      |
| Employed                                     | 301        | 89.0       | 141      | 91.0       | n/a      | n/a        |                      |
| Clinical characteristics                     |            |            |          |            |          |            |                      |
| Diagnosis                                    |            |            |          |            |          |            | 0.170                |
| Lymphoma<br>Germ cell                        | n/a        | n/a        | 59       | 38.1       | 91       | 29.5       |                      |
| tumor  | n/a        | n/a        | 45       | 29.0       | 117      | 37.9       |                      |
| Sarcoma<br>Leukemia                          | n/a<br>n/a | n/a<br>n/a | 14<br>13 | 9.0<br>8.4 | 17<br>28 | 5.5<br>9.1 |                      |

#### **RESULTS**

# Characteristics of the study population

In total, 469 survivors were eligible to participate in the study, of which 389 (100%) had a current address and could be contacted (Figure 1). Of those contacted, 160 (41%) filled in the questionnaire, and 155 completed the SF-12 items (40%; 96 (62%) males). Participants and non-participants did not differ regarding their socio-demographic and cancer-related characteristics (Table 1). Participants' mean age at study was 34.0 years. Mean age at diagnosis was 21.6 years, and mean time since diagnosis was 12.4 years. Lymphomas (38%) and germ cell tumors (29%) were the most common diagnoses. Of all participants, 22 (14%) reported having had a relapse, 11 (7%) a second malignancy, and 41 (27%) reported having at least one late effect.

The control population (n=350; 140 (40%) males) had a mean age of 35.5 years.




Fig. 1 Flow chart of our study participants

Eligible survivors had been diagnosed with central nervous system tumor (CNS), germ cell tumor, lymphoma, leukemia, neuroblastoma, renal, hepatic, and bone tumor, as well as soft tissue sarcoma, between 1990 and 2005, aged between 16-25 years at the time of diagnosis and were  $\geq 5$  years after diagnosis at time of study

Table 1 (continued)

| Table 1 (continue  | General population |      | Particij | oants | Non-<br>particij | oants |                              |
|--|--------------------|------|----------|-------|------------------|-------|------------------------------|
|  | N                  | %    | N        | %     | N                | %     | <i>p</i> -value <sup>a</sup> |
| CNS tumor  | n/a                | n/a  | 13       | 8.4   | 36               | 11.7  |                              |
| other  | n/a                | n/a  | 11       | 7.1   | 20               | 6.5   |                              |
| Treatment <sup>b</sup>                                   |                    |      |          |       |                  |       | 0.507                        |
| Surgery only   | n/a                | n/a  | 54       | 34.8  | 108              | 35.0  |                              |
| Chemotherapy <sup>c</sup>                                | n/a                | n/a  | 31       | 20.0  | 63               | 20.4  |                              |
| Radiotherapy <sup>d</sup><br>Age at diagnosis<br>(years) | n/a                | n/a  | 39       | 25.2  | 59               | 19.1  | 0.439                        |
| 16-20  | n/a                | n/a  | 67       | 43.2  | 122              | 39.5  |                              |
| 21-25  | n/a                | n/a  | 88       | 56.8  | 187              | 60.5  |                              |
| Time since diag-<br>nosis (years)                        |                    |      |          |       |                  |       | 0.971                        |
| 5-10   | n/a                | n/a  | 57       | 36.8  | 111              | 35.9  |                              |
| 11-15  | n/a                | n/a  | 50       | 32.3  | 99               | 32.0  |                              |
| 16+  | n/a                | n/a  | 48       | 31.0  | 99               | 32.0  |                              |
| Relapse  |                    |      |          |       |                  |       |                              |
| No relapse   | n/a                | n/a  | 133      | 85.8  | n/a              | n/a   |                              |
| Relapse<br>Second malig-<br>nancy                        | n/a                | n/a  | 22       | 14.2  | n/a              | n/a   |                              |
| No second malignancy                                     | n/a                | n/a  | 144      | 92.9  | n/a              | n/a   |                              |
| Second<br>malignancy                                     | n/a                | n/a  | 11       | 7.1   | n/a              | n/a   |                              |
| Late effects <sup>b</sup>                                |                    |      |          |       |                  |       |                              |
| No late effects  | n/a                | n/a  | 111      | 71.6  | n/a              | n/a   |                              |
| Late effects   | n/a                | n/a  | 41       | 26.5  | n/a              | n/a   |                              |
| Type of late effect                                      |                    |      |          |       |                  |       |                              |
| Psychological late effect                                | n/a                | n/a  | 4        | 9.8   | n/a              | n/a   |                              |
| Somatic late effect                                      | n/a                | n/a  | 28       | 66.3  | n/a              | n/a   |                              |
| Both   | n/a                | n/a  | 9        | 22.0  | n/a              | n/a   |                              |
|  | Mean               | SD   | Mean     | SD    | Mean             | SD    | <i>p</i> -value <sup>e</sup> |
| Age at study (years)                                     | 35.5               | 7.21 | 34.0     | 5.87  | 34.2             | 5.62  | 0.722                        |
| Age at diagnosis (years)                                 | n/a                | n/a  | 21.6     | 2.89  | 21.7             | 2.92  | 0.727                        |
| Time since diagnosis (years)                             | n/a                | n/a  | 12.4     | 4.74  | 12.5             | 4.78  | 0.831                        |

<sup>&</sup>lt;sup>a</sup> p-values from chi-square test

<sup>&</sup>lt;sup>b</sup> Missing values; percentages are based on the total number of participants/non-participants/general population

<sup>&</sup>lt;sup>c</sup> Chemotherapy (may have had surgery but not radiotherapy)

<sup>&</sup>lt;sup>d</sup> Radiotherapy (may have had surgery and/or chemotherapy)

<sup>&</sup>lt;sup>e</sup> *p*-value from two sample t-test

# Aim 1: Comparison of HRQoL with general population

Survivors had significantly lower PCS scores than controls (mean: 52.5 vs. 54.7, p < 0.001), both in males (52.7 vs. 54.9, p = 0.004), and females (52.1 vs. 54.2, p = 0.032, Figure 2). Male survivors reported better mental health than controls (55.2 vs. 53.3, p = 0.078) and females slightly worse (49.8 vs 51.8, p = 0.285, Figure 3). The proportions of survivors and controls with poor physical health (11.0% vs. 9%, p = 0.554) or poor mental health (24.0% vs. 21%, p = 0.412) did not differ.




Fig. 2 Comparison of physical health measured by the Physical Component Summary (PCS) in AYA cancer survivors and the general population (mean scores and 95% confidence intervals) Abb.: AYA, adolescent and young adult, CI, Confidence Interval, HRQoL, health related quality of life, PCS, Physical Component Summary. Higher scores indicate better physical health

\*  $p \le 0.05$ , \*\*  $p \le 0.01$ , \*\*\*  $p \le 0.001$ 




Fig. 3 Comparison of mental health measured by the Mental Component Summary (MCS) in AYA cancer survivors and the general population (mean scores and 95% confidence intervals) Abb.: see Fig.2, MCS, Mental Component Summary

#### Aim 2: Characteristics associated with poor HRQoL

#### Poor physical health

In univariable logistic regression, survivors with a migration background (odds ratio (OR) = 5.34, 95% confidence interval (CI): 1.87-15.26, p=0.002), those who were unemployed (OR=8.86, CI: 2.61-30.16, p<0.001) and those with late effects (OR=2.75, CI: 1.00-7.67, p=0.054) were more likely to report poor physical health (Table 2). Survivors who had compulsory education only, compared to higher education, tended to be more likely to report poor physical health (OR=2.37, CI: 0.54-10.42, p = 0.253). No age-dependent difference in reported HRQoL at study was found. There was no difference in physical health regarding age at diagnosis, type of cancer diagnosis, treatment, relapse or second malignancies.

In multivariable regression, only migration background (OR=4.63, CI: 1.50-14.28, p=0.008) and unemployment (OR=7.66, CI: 1.93-30.34, p=0.005) remained significantly associated with poor physical health.

#### Poor mental health

In univariable regression, females (OR=3.74, CI: 1.73-8.09, p=0.001), those with a migration background (OR=4.53, CI: 1.97-10.37, p<0.001), the unemployed (OR=7.26, CI: 2.26-23.38, p=0.001) and those reporting late effects (OR=8.02, CI: 3.49-18.42, p<0.001) were more likely to report poor mental health (Table 3). Additionally, survivors who had been diagnosed with germ cell tumors were less likely to report poor mental health (OR=0.24, CI: 0.08-0.71; p=0.010) than lymphoma survivors.

In multivariable regression, being female (OR=2.69, CI: 0.87-7.51, p=0.057), having a migration background (OR=5.82, CI: 1.98-17.07, p=0.004) and reporting late effects (OR=5.91, CI: 2.16-16.14, p<0.001) remained significantly associated with reporting poor mental health.

# DISCUSSION

Our findings show that overall, AYA cancer survivors have significantly worse physical health than the general population. Poorer physical health was reported among those with a migration background and those who were unemployed. Survivors reported similar mental health as the general population. Male survivors reported better mental health, whereas female survivors reported slightly worse mental health than controls. Survivors with a migration background and those reporting late effects were at particular risk to have poor mental health.

Table 2: Characteristics associated with poor physical health in AYA cancer survivors (low physical health if SF-12 Physical Component Summary (PCS) score  $\leq 45.5^a$ )

|                                       | Survivors reporting poor health |      |        | Univariable regression |                 |        | Multivariable regression <sup>b</sup> |                              |  |
|---------------------------------------|---------------------------------|------|--------|------------------------|-----------------|--------|---------------------------------------|------------------------------|--|
|                                       | N                               | %°   | $OR^d$ | [95% CI]°              | <i>p</i> -value | $OR^d$ | [95% CI]°                             | <i>p</i> -value <sup>f</sup> |  |
|                                       | 17                              | 11.0 |        |                        |                 |        |                                       |                              |  |
| Sex                                   |                                 |      |        |                        | 0.421           |        |                                       |                              |  |
| Male                                  | 9                               | 9.4  | 1      |                        |                 |        |                                       |                              |  |
| Female                                | 8                               | 13.6 | 1.52   | 0.55 - 4.18            |                 |        |                                       |                              |  |
| Age at study                          |                                 |      |        |                        | $0.870^{\rm g}$ |        |                                       |                              |  |
| 20-29                                 | 5                               | 12.0 | 1      |                        |                 |        |                                       |                              |  |
| 30-39                                 | 8                               | 9.8  | 0.80   | 0.24 - 2.62            |                 |        |                                       |                              |  |
| 40+                                   | 4                               | 13.0 | 1.10   | 0.27 - 4.47            |                 |        |                                       |                              |  |
| Migration background                  |                                 |      |        |                        | 0.002           |        |                                       | 0.008                        |  |
| No                                    | 8                               | 6.6  | 1      |                        |                 | 1      |                                       |                              |  |
| Yes                                   | 9                               | 27.3 | 5.34   | 1.87 - 15.26           |                 | 4.63   | 1.50 - 14.28                          |                              |  |
| Partner                               |                                 |      |        |                        | 0.271           |        |                                       |                              |  |
| No                                    | 2                               | 5.7  | 1      |                        |                 |        |                                       |                              |  |
| Yes                                   | 15                              | 12.5 | 2.36   | 0.51 - 10.85           |                 |        |                                       |                              |  |
| Education<br>Compulsory<br>schooling  | 3                               | 25.0 | 2.37   | 0.54 - 10.42           | 0.214           |        |                                       |                              |  |
| Vocational training                   | 9                               | 12.3 | 1      |                        |                 |        |                                       |                              |  |
| Upper Secondary /university education | 4                               | 5.8  | 0.44   | 0.13 - 1.50            |                 |        |                                       |                              |  |
| Unemployment                          |                                 |      |        |                        | <0.001          |        |                                       | 0.005                        |  |
| No                                    | 11                              | 7.8  | 1      |                        |                 | 1      |                                       |                              |  |
| Yes                                   | 6                               | 42.9 | 8.86   | 2.61 - 30.16           |                 | 7.66   | 1.93 - 30.34                          |                              |  |
| Diagnosis                             |                                 |      |        |                        | $0.518^{g}$     |        |                                       |                              |  |
| Lymphoma                              | 5                               |      | 1      |                        |                 |        |                                       |                              |  |
| Germ cell tumor                       | 3                               |      | 0.77   | 0.17 - 3.41            |                 |        |                                       |                              |  |
| Sarcoma                               | 2                               |      | 1.80   | 0.31 - 10.41           |                 |        |                                       |                              |  |
| Leukemia                              | 2                               |      | 1.96   | 0.34 - 11.45           |                 |        |                                       |                              |  |
| CNS tumor                             | 2                               |      | 1.96   | 0.34 - 11.45           |                 |        |                                       |                              |  |
| Other <sup>h</sup>                    | 3                               |      | 4.05   | 0.81 - 20.31           |                 |        |                                       |                              |  |
| Treatment                             |                                 |      |        |                        | 0.485           |        |                                       |                              |  |
| Surgery                               | 7                               | 13.0 | 1      |                        |                 |        |                                       |                              |  |
| Chemotherapy                          | 5                               | 16.0 | 1.29   | 0.37 - 4.48            |                 |        |                                       |                              |  |
| Radiotherapy                          | 3                               | 7.7  | 0.56   | 0.14 - 2.32            |                 |        |                                       |                              |  |
| Age at diagnosis                      |                                 |      |        |                        | 0.736           |        |                                       |                              |  |
| 16-20                                 | 8                               | 11.9 | 1      |                        |                 |        |                                       |                              |  |
| 21-25                                 | 9                               | 10.2 | 0.84   | 0.31 - 2.30            |                 |        |                                       |                              |  |

Table 2 (continued)

|                      | Survivors reporting poor health |      | Univariable regression |                       |         | Multivariable regression <sup>b</sup> |                       |                              |
|----------------------|---------------------------------|------|------------------------|-----------------------|---------|---------------------------------------|-----------------------|------------------------------|
|                      | N                               | % °  | OR <sup>d</sup>        | [95% CI] <sup>e</sup> | p-value | $OR^d$                                | [95% CI] <sup>e</sup> | <i>p</i> -value <sup>f</sup> |
| Time since diagnosis |                                 |      |                        |                       | 0.922   |                                       |                       |                              |
| 5-10 years           | 7                               | 12.3 | 1                      |                       |         |                                       |                       |                              |
| 11-15 years          | 5                               | 10.0 | 0.79                   | 0.24 - 2.68           |         |                                       |                       |                              |
| 16+ years            | 5                               | 10.4 | 0.83                   | 0.25 - 2.81           |         |                                       |                       |                              |
| Relapse              |                                 |      |                        |                       | 0.319   |                                       |                       |                              |
| No                   | 16                              | 12.0 | 1                      |                       |         |                                       |                       |                              |
| Yes                  | 1                               | 4.5  | 0.35                   | 0.04 - 2.77           |         |                                       |                       |                              |
| Second malignancy    |                                 |      |                        |                       | 0.837   |                                       |                       |                              |
| No                   | 16                              | 11.0 | 1                      |                       |         |                                       |                       |                              |
| Yes                  | 1                               | 9.0  | 0.80                   | 0.10 - 6.67           |         |                                       |                       |                              |
| Late effects         |                                 |      |                        |                       | 0.054   |                                       |                       | 0.397                        |
| No                   | 9                               | 8.0  | 1                      |                       |         | 1                                     |                       |                              |
| Yes                  | 8                               | 19.5 | 2.75                   | 1.00 - 7.67           |         | 1.67                                  | 0.52 - 5.39           |                              |

<sup>&</sup>lt;sup>a</sup> Cut-off calculated by deducting 6.97 points from the age-specific mean as indicator for poor physical health

Our findings are in line with findings from a recent systematic review on the quality of life in AYA cancer patients and survivors [15] and findings from an additional study on AYA cancer survivors' HRQoL in the US [23]. The studies in the systematic review assessed quality of life with a variety of validated tools like the Pediatric Quality of Life Inventory, the European Organization for Research and Treatment of Cancer's quality of life questionnaire, the Quality of life Behavioral Risk Factor Surveillance System and the Functional Assessment of Cancer Therapy-Bone Marrow Transplant, but also with their own instruments [15]. Nineteen studies used quantitative methods, 13 studies used qualitative methods and a mixed-methods approach was used by three studies [15]. Both the systematic review and the study from the US,

using the SF-12, concluded that, overall, in comparison to the general population AYA cancer survivors were more likely to have poor or impaired quality of life. The impaired HRQoL was observable early on after diagnosis. In contrary, a study from the UK comparing AYA cancer survivors' HRQoL with normative data concluded that physical and mental health measured by the SF-12 were comparable in both groups [22]. A possible explanation why the survivors' mental health in our study was not significantly worse but comparable with the norm population's mental health could be the link between cancer survival and post-traumatic growth and resilience in cancer survivors [36,12].

<sup>&</sup>lt;sup>b</sup> In the multivariable model, we included all variables that were significantly associated  $(p \le 0.1)$  with low PCS in the univariable logistic regression model

<sup>&</sup>lt;sup>c</sup> Percentage of survivors reporting poor health in specific subcategory

<sup>&</sup>lt;sup>d</sup> Odds ratio (OR for scoring 6.97 points below the age-specific mean (Physical Component Summary Score ≤ 45.5)

e 95% confidence interval

<sup>&</sup>lt;sup>f</sup>Global *p*-value calculated with likelihood ratio test (multivariable regression)

<sup>&</sup>lt;sup>g</sup>Global *p*-value calculated with chi-square test (univariable regression)

<sup>&</sup>lt;sup>h</sup> Other malignant cancers ranking below the top five most common cancers in the AYA population p-values≤ 0.1 are depicted in bold

**Table 3:** Characteristics associated with poor mental health in AYA cancer survivors (low mental health if SF-12 Mental Component Summary (MCS) score  $\leq 47.5^a$ )

|  | Survivors reporting poor health |      |        | Univariable regression |                 |        | Multivariable regression <sup>b</sup> |                              |  |
|--|---------------------------------|------|--------|------------------------|-----------------|--------|---------------------------------------|------------------------------|--|
|  | N                               | % c  | $OR^d$ | [95% CI]°              | <i>p</i> -value | $OR^d$ | [95% CI] <sup>e</sup>                 | <i>p</i> -value <sup>f</sup> |  |
|  | 37                              | 24.0 |        |                        |                 |        |                                       |                              |  |
| Sex                                    |                                 |      |        |                        | 0.001           |        |                                       | 0.057                        |  |
| Male                                   | 14                              | 14.6 | 1      |                        |                 | 1      |                                       |                              |  |
| Female                                 | 23                              | 39.0 | 3.74   | 1.73 - 8.09            |                 | 2.69   | 0.87 - 7.51                           |                              |  |
| Age at study                           |                                 |      |        |                        | $0.709^{g}$     |        |                                       |                              |  |
| 20-29                                  | 12                              | 29.0 | 1      |                        |                 |        |                                       |                              |  |
| 30-39                                  | 18                              | 22.0 | 0.70   | 0.30 - 1.64            |                 |        |                                       |                              |  |
| 40+                                    | 7                               | 22.6 | 0.73   | 0.25 - 2.14            |                 |        |                                       |                              |  |
| Migration background                   |                                 |      |        |                        | <0.001          |        |                                       | 0.004                        |  |
| No                                     | 21                              | 17.2 | 1      |                        |                 | 1      |                                       |                              |  |
| Yes                                    | 16                              | 48.5 | 4.53   | 1.97 - 10.37           |                 | 5.82   | 1.98 - 17.07                          |                              |  |
| Partner                                |                                 |      |        |                        | 0.104           |        |                                       |                              |  |
| No                                     | 12                              | 34.3 | 1      |                        |                 |        |                                       |                              |  |
| Yes                                    | 25                              | 20.8 | 0.50   | 0.22 - 1.15            |                 |        |                                       |                              |  |
| Education                              |                                 |      |        |                        | 0.112           |        |                                       |                              |  |
| Compulsory schooling                   | 5                               | 41.7 | 1.89   | 0.54 - 6.66            |                 |        |                                       |                              |  |
| Vocational training                    | 20                              | 27.4 | 1      |                        |                 |        |                                       |                              |  |
| Upper Secondary / university education | 11                              | 16.0 | 0.50   | 0.22 - 1.15            |                 |        |                                       |                              |  |
| Unemployment                           |                                 |      |        |                        | 0.001           |        |                                       | 0.133                        |  |
| No                                     | 28                              | 19.9 | 1      |                        |                 | 1      |                                       |                              |  |
| Yes                                    | 9                               | 64.3 | 7.26   | 2.26 - 23.38           |                 | 3.66   | 0.87 - 15.47                          |                              |  |
| Diagnosis                              |                                 |      |        |                        | 0.039           |        |                                       | 0.114                        |  |
| Lymphoma                               | 20                              | 54.0 | 1      |                        |                 |        |                                       |                              |  |
| Germ cell tumor                        | 5                               | 14.0 | 0.24   | 0.08 - 0.71            |                 | 0.25   | 0.05 - 0.89                           |                              |  |
| Sarcoma                                | 1                               | 3.0  | 0.15   | 0.02 - 1.23            |                 | 0.07   | 0.00 - 1.35                           |                              |  |
| Leukemia                               | 4                               | 11.0 | 0.87   | 0.24 - 3.17            |                 | 0.49   | 0.09 - 2.63                           |                              |  |
| CNS tumor                              | 3                               | 7.0  | 0.59   | 0.14 - 2.37            |                 | 0.43   | 0.80 - 2.35                           |                              |  |
| Other <sup>h</sup>                     | 4                               | 11.0 | 1.11   | 0.29 - 4.26            |                 | 0.92   | 0.18 - 4.76                           |                              |  |
| Treatment                              |                                 |      |        |                        | 0.398           |        |                                       |                              |  |
| Surgery                                | 11                              | 20.4 | 1      |                        |                 |        |                                       |                              |  |
| Chemotherapy                           | 6                               | 19.4 | 0.94   | 0.31 - 2.85            |                 |        |                                       |                              |  |
| Radiotherapy                           | 11                              | 28.0 | 1.54   | 0.59 - 4.02            |                 |        |                                       |                              |  |
| Age at diagnosis                       |                                 |      |        |                        | 0.702           |        |                                       |                              |  |
| 16-20                                  | 17                              | 25.4 | 1      |                        |                 |        |                                       |                              |  |
| 21-25                                  | 20                              | 22.7 | 0.87   | 0.41 - 1.82            |                 |        |                                       |                              |  |

Table 3 (continued)

|                      | Survivors reporting poor health |      | Univariable regression |                       |                    | Multivariable regression <sup>b</sup> |              |                      |
|----------------------|---------------------------------|------|------------------------|-----------------------|--------------------|---------------------------------------|--------------|----------------------|
|                      | N                               | % c  | OR <sup>d</sup>        | [95% CI] <sup>e</sup> | <i>p</i> -value    | OR <sup>d</sup>                       | [95% CI°     | p-value <sup>f</sup> |
| Time since diagnosis |                                 |      |                        |                       | 0.346 <sup>g</sup> |                                       |              |                      |
| 5-10 years           | 15                              | 26.0 | 1                      |                       |                    |                                       |              |                      |
| 11-15 years          | 14                              | 28.0 | 1.09                   | 0.46 - 2.56           |                    |                                       |              |                      |
| 16+ years            | 8                               | 17.0 | 0.56                   | 0.21 - 1.46           |                    |                                       |              |                      |
| Relapse              |                                 |      |                        |                       | 0.687              |                                       |              |                      |
| No                   | 31                              | 23.0 | 1                      |                       |                    |                                       |              |                      |
| Yes                  | 6                               | 27.0 | 1.23                   | 0.44 - 3.42           |                    |                                       |              |                      |
| Second malignancy    |                                 |      |                        |                       | 0.259              |                                       |              |                      |
| No                   | 36                              | 25.0 | 1                      |                       |                    |                                       |              |                      |
| Yes                  | 1                               | 9.0  | 0.30                   | 0.04 - 2.43           |                    |                                       |              |                      |
| Late effects         |                                 |      |                        |                       | < 0.001            |                                       |              | <0.001               |
| No                   | 14                              | 13.0 | 1                      |                       |                    | 1                                     |              |                      |
| Yes                  | 22                              | 54.0 | 8.02                   | 3.49 - 18.42          |                    | 5.91                                  | 2.16 - 16.14 |                      |

<sup>&</sup>lt;sup>a</sup>Cut-off calculated by deducting 6.24 points of the age-specific mean as indicator for poor mental health

In our study, a strong determinant of poorer physical and mental health was having a migration background. Similar to our findings, the above mentioned study from the US found that it was more likely to have poor physical health among participants with a different ethnic background, namely Hispanic responders, compared to Whites [23].

Even though it is difficult to make general statements about the health status of migrants because of the population's diversity, data from the National Health Report in Switzerland in 2015 showed that the population with migration background had overall a worse health status than the native Swiss population [37]. Despite using interpreting resources and the health professionals' language skills, cultural differences in understanding and meaning making of health and sickness may persist [38,39]. Cultural differences and individual characteristics may contribute to the different outcomes between those with migration background and those without. In addition to that, two US studies found that physical health in cancer survi-

vors was also affected by having a lower educational degree [23,40], which is a tendency that can be observed in our findings..

HRQoL was also affected by employment status. Those being unemployed had significantly poorer physical and mental health than those who were employed. This is in accordance with data from the Swiss National Health Report 2015 showing that the number of people who perceive their health status as (very) good is lower in the unemployed and they additionally suffer more from modest to severe depression than those who were employed [37]. Employment status and health affect each other in many and bidirectional ways and due to non-availability of further information from our participants on the reasons for unemployment, we are not able to draw conclusions on the causality path. A possible explanation could be the healthy worker effect [37,41], i.e. with better health a survivor is more likely to get employed. Another explanation could be that the survivors' HRQoL was negatively affected by their unemployment, which is in line with findings where unemployment at age 26-55 was found to have

<sup>&</sup>lt;sup>b</sup> In the multivariable model, we included all variables that were significantly associated  $(p \le 0.1)$  with low MCS in the univariable logistic regression model

c Percentage of survivors reporting poor health in specific subcategory

<sup>&</sup>lt;sup>d</sup> Odds ratio (OR for scoring 6.24 points below the age-specific mean (Mental Component Summary Score ≤ 47.5)

e95% confidence interval

<sup>&</sup>lt;sup>f</sup>Global p-value calculated with likelihood ratio test (multivariable regression)

<sup>&</sup>lt;sup>g</sup>Global *p*-value calculated with chi-square test (univariable regression)

<sup>&</sup>lt;sup>h</sup> Other malignant cancers ranking below the top five most common cancers in the AYA population p-values  $\leq 0.1$  are depicted in bold

major effect on HRQoL, compared to younger or older age [41].

In general males scored higher than females with a significant difference in mental health. This is in line with gender-specific differences found by Geue et al. in 2012 in short-term survivors of young adult cancer [21] and results from the German Socio Economic Panel (SOEP) survey from 2002 [27]. The gender-specific difference persists across the whole population, independent of age and health status [27]. This might explain why in our and a study from the US, female survivors and females in the norm population scored lower in their physical and mental health than males [40]. Sex differences may persist due to the diverse impact of health outcomes such as concerns on body appearance, questions on fertility and sexual functioning, physical, psychological, and psychosocial late effects [11].

Similar to our findings, other studies found a strong association between more late effects and poorer physical and mental health (though not statistically significant for physical health in our study) [22]. In accordance with these findings, studies from the US found a strong association between having symptoms and an increased likelihood to report poorer physical and mental health [23,40]. In addition, our findings were also consistent with studies among childhood cancer survivors, where physical and psychological late effects were strong determinants of poorer HRQoL [5,10-13].

Regarding diagnosis, studies show different results. Our results are similar to the UK study findings where survivors diagnosed with germ cell tumors overall reported better HRQoL than others [22]. One study from the US found that former germ cell tumor patients were more likely to report better physical than mental health [23]. However, studies agree that the more intense the received treatment and the higher the number of late effects a survivor has, the worse the HRQoL [23,40]. More intense treatments like chemotherapy and/or radiotherapy have been associated with poor mental health and are risk factors for a diverse number of late effects [17,40,3]. Our study results suggest that there might be an association between treatment and mental health, by showing an elevated odds ratio for radiotherapy (may have had surgery and/or chemotherapy) compared to chemotherapy (may have had surgery; Table 3). However, our results did not reach significance level, which might be ascribed to a reduced accuracy of effect estimates in subgroup analyses due to a small sample size of our study population.

Our findings complement other studies pointing out aspects in need of intervention or additional support, such as reducing disparities due to migration background, and support and counseling in education and employment issues. Improved outcomes may be achieved by providing culturally adapted brochures, information material, and services in modern and acceptable format for AYAs, such as online-platforms, social networks and events. Our results also indicate that females may be in need for more psychological support and counseling than what has been provided until today. Follow-up targeting gender-specific outcomes and provision of multidisciplinary services may be helpful. Health promotion and guidance against risky health behaviors can help improve physical and mental health and lead to better HRQoL [18,14,7].

# Limitations and strengths

The relatively small sample size of AYA cancer survivors participating in our study limits the effect-accuracy of our statistical analyses, especially in subgroup analyses. The response rate of 40% may indicate that those who were in worse condition did not want to participate in the study. These limitations are comparable to those of other studies using questionnaires. The restriction of our study population in regard to specific diagnostic groups limits the generalizability of our findings. Another limitation is the cross-sectional design which prevents us from drawing any causal explanations.

A major strength was the use of population-based data combined with clinical information from the Cancer Registry Zurich and Zug, and the comparison with an adequate Swiss control group within the same age range. Another strength is the use of the prominently used and validated SF-12 questionnaire in combination with specifically calculated cut-offs for our study population.

#### Conclusion

Our results show that most of the AYA cancer survivors report satisfactory HRQoL. However there are relevant subgroups at higher risk for poor HRQoL and in need for adequate and specialized care. It is necessary to re-evaluate the existing support and consultation services with respect to the vulnerable subgroups. Additionally, mental health in particular was associated with several socio-demographic and cancer-related characteristics. Further research in AYAs is of uttermost importance in order to improve health related and psychological outcomes in this continuously growing population.

ACKNOWLEDGEMENTS We wish to thank all participants for the time and effort invested in answering the questionnaires and the Cancer Registry Zurich and Zug for the provided information and data.

COMPLIANCE WITH ETHICAL STANDARDS All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards."

CONFLICT OF INTEREST The authors declare that they have no conflict of interest.

INFORMED CONSENT Informed consent was obtained from all individual participants included in the study.

FUNDING This work was supported by the Swiss National Science Foundation (Ambizione fellowship PZ00P3\_121682/1 and PZ00P3\_141,722 to GM; grant 100019\_153268/1) and Cancer Research Switzerland (Grant No. KFS-3955-08-2016).

#### REFERENCES

- 1. Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, Maule MM, Merletti F, Gatta G (2016) Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. The Lancet Oncology 17 (7):896-906. doi:10.1016/s1470-2045(16)00162-5
- 2. Arndt V, Feller A, Hauri D, Heusser R, Junker C, Kuehni C, Lorez M, Pfeiffer V, Roy E, Schindler M (2016) Schweizerischer Krebsbericht 2015 Stand und Entwicklungen [Cancer in Switzerland 2015 Situation and development]. Federal Statistical Office FSO, Neuchâtel
- 3. Woodward E, Jessop M, Glaser A, Stark D (2011) Late effects in survivors of teenage and young adult cancer: does age matter? Ann Oncol 22 (12):2561-2568. doi:10.1093/annonc/mdr044
- 4. Brown MC, Pearce MS, Bailey S, Skinner R (2016) The long-term psychosocial impact of cancer: the views of young adult survivors of childhood cancer. Eur J Cancer Care 25 (3):428–439. doi:10.1111/ecc.12380
- 5. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, Leisenring WM, Meacham LR, Mertens AC, Mulrooney DA, Oeffinger KC, Packer RJ, Robison LL, Sklar CA (2009) Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings. J Clin Oncol
- 6. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355 (15):1572-1582
- 7. Warner EL, Nam GE, Zhang Y, McFadden M, Wright J, Spraker-Perlman H, Kinney AY, Oeffinger KC, Kirchhoff AC (2016) Health behaviors, quality of life, and psychosocial health among survivors of adolescent and young adult cancers. J Cancer Surviv 10 (2):280-290. doi:10.1007/s11764-015-0474-7
- 8. Centers for Disease Control and Prevention. Atlanta G, CDC N (2000) Measuring Healthy Days. Atlanta, Georgia
- 9. Evans DR (1994) Enhancing Quality of Life in the Population at Large. Social Indicators Research 33 (1/3):47-88
- 10. Essig S, von der Weid NX, Strippoli MP, Rebholz CE, Michel G, Rueegg CS, Niggli FK, Kuehni CE (2012) Health-Related Quality of Life in Long-Term Survivors of Relapsed Childhood Acute Lymphoblastic Leukemia. PLoS One 7 (5):e38015. doi:10.1371/journal.pone.0038015

- 11. Nightingale CL, Quinn GP, Shenkman EA, Curbow BA, Zebrack BJ, Krull KR, Huang IC (2011) Health-Related Quality of Life of Young Adult Survivors of Childhood Cancer: A Review of Qualitative Studies. J Adolesc Young Adult Oncol 1 (3):124-132. doi:10.1089/jayao.2011.0033
- 12. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, von der Weid NX, Michel G, Kuehni CE (2013) Health-related quality of life in survivors of childhood cancer: the role of chronic health problems. J Cancer Surviv 7 (4):511-522. doi:10.1007/s11764-013-0288-4
- 13. Wengenroth L, Gianinazzi ME, Rueegg CS, Luer S, Bergstraesser E, Kuehni CE, Michel G (2015) Health-related quality of life in young survivors of childhood cancer. Qual Life Res. doi:10.1007/s11136-015-0961-3
- 14. Murnane A, Gough K, Thompson K, Holland L, Conyers R (2015) Adolescents and young adult cancer survivors: exercise habits, quality of life and physical activity preferences. Support Care Cancer 23 (2):501-510. doi:10.1007/s00520-014-2446-2
- 15. Quinn GP, Goncalves V, Sehovic I, Bowman ML, Reed DR (2015) Quality of life in adolescent and young adult cancer patients: a systematic review of the literature. Patient Relat Outcome Meas 6:19-51. doi:10.2147/PROM.S51658
- 16. Tai E, Buchanan N, Townsend J, Fairley T, Moore A, Richardson LC (2012) Health status of adolescent and young adult cancer survivors. Cancer 118 (19):4884-4891. doi:10.1002/cncr.27445
- 17. Bleyer A (2007) Young adult oncology: the patients and their survival challenges. CA: a cancer journal for clinicians 57 (4):242-255
- 18. Docherty SL, Kayle M, Maslow GR, Santacroce SJ (2015) The Adolescent and Young Adult with Cancer: A Developmental Life Course Perspective. Seminars in oncology nursing 31 (3):186-196. doi:10.1016/j.soncn.2015.05.006
- 19. Kirchhoff AC, Yi J, Wright J, Warner EL, Smith KR (2012) Marriage and divorce among young adult cancer survivors. J Cancer Surviv 6 (4):441-450. doi:10.1007/s11764-012-0238-6
- 20. Lang MJ, Giese-Davis J, Patton SB, Campbell DJT (2017) Does age matter? Comparing post-treatment psychosocial outcomes in young adult and older adult cancer survivors with their cancer-free peers. Psychooncology. doi:10.1002/pon.4490
- 21. Geue K, Sender A, Schmidt R, Richter D, Hinz A, Schulte T, Brahler E, Stobel-Richter Y (2014) Gender-specific quality of life after cancer in young adulthood: a comparison with the general population. Qual Life Res 23 (4):1377-1386. doi:10.1007/s11136-013-0559-6
- 22. Absolom K, Eiser C, Michel G, Walters SJ, Hancock BW, Coleman RE, Snowden JA, Greenfield DM (2009) Follow-up care for cancer survivors: views of the younger adult. Br J Cancer 101 (4):561-567. doi:6605213 [pii] 10.1038/sj.bjc.6605213
- 23. DeRouen MC, Smith AW, Tao L, Bellizzi KM, Lynch CF, Parsons HM, Kent EE, Keegan THM, for the A. Y. A. Hope Study Collaborative Group (2015) Cancer-related information needs and cancer's impact on control over life influence health-related quality of life among adolescents and young adults with cancer. Psychooncology:doi:10.1002/pon.3730. doi:10.1002/pon.3730
- 24. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli M-PF, Niggli FK, Egger M, von der Weid NX, for the Swiss Paediatric Oncology Group (2012) Cohort profile: The Swiss Childhood Cancer Survivor Study. Int J Epidemiol 41 (6):1553-1564. doi:10.1093/ije/dyr142
- 25. Ware JE, Kosinski M, Keller SD (1995) How to score the SF-12 Physical and mental health summary scales. QualityMetric Inc, Lincoln, RI
- 26. Flatz A, Casillas A, Stringhini S, Zuercher E, Burnand B, Peytremann-Bridevaux I (2015) Association between education and quality of diabetes care in Switzerland. Int J Gen Med 8:87-92. doi:10.2147/IJGM.S77139
- 27. Nübling M, Andersen HH, Mühlbacher A, Schupp J, Wagner GG (2007) Computation of Standard Values for Physical and

- Mental Health Scale Scores Using the SOEP Version of SF12v2. Schmollers Jahrbuch: Journal of Applied Social Science Studies / Zeitschrift für Wirtschafts- und Sozialwissenschaften 127 (1):171-182
- 28. Perneger TV, Hudelson PM, Bovier PA (2004) Health and happiness in young Swiss adults. Quality of Life Research 13 (1):171-178. doi:10.1023/b;qure.0000015314.97546.60
- 29. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M (1998) Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project. Journal of Clinical Epidemiology 51 (11):1171–1178. doi:10.1016/S0895-4356(98)00109-7
- 30. Sanderson M, McNamara, K.P, Neerings, K. (2004) Health Status in Utah: The Medical Outocmes Study SF-12 (2001) (trans: Health UDo). Utah Department of Health, Salt Lake City, UT: Utah Department of Health
- 31. Mader LV, J.; Christen, S.; Baenziger, J.; Roser, K.; Dehler, S.; Michel, G. Education, employment and marriage in long-term survivors of teenage and young adult cancer compared with healthy controls. Swiss Med Wkly. doi:10.4414/smw.2017.14419
- 32. Kuehni CE, Strippoli M-PF, Rueegg CS, Rebholz CE, Bergstraesser E, Grotzer M, von der Weid NX, Michel G (2012) Educational achievement in Swiss childhood cancer survivors compared with the general population. Cancer 118 (5):1439-1449. doi:10.1002/cncr.26418
- 33. Die Bevölkerung der Schweiz 2015 (2016). Bundesamt für Statistik. Neuchâtel
- 34. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P (2005) International Classification of Childhood Cancer, third edition. Cancer 103 (7):1457-1467

- 35. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA: a cancer journal for clinicians 66 (1):7-30. doi:10.3322/caac.21332
- 36. Bellizzi KM, Smith AW, Reeve BB, Alfano CM, Bernstein L, Meeske K, Baumgartner KB, Ballard-Barbash RR (2010) Posttraumatic growth and health-related quality of life in a racially diverse cohort of breast cancer survivors. J Health Psychol 15 (4):615-626. doi:15/4/615 [pii] 10.1177/135910530935636437. Bachmann NB, L.; Kohler, D. (2015) Gesundheit in der Schweiz Fokus chronische Erkrankungen, Nationaler Gesundheitsbericht 2015. Bern
- 38. Harzing A-W (2006) Response Styles in Cross-national Survey Research. International Journal of Cross Cultural Management 6 (2):243-266. doi:10.1177/1470595806066332
- 39. Schulz M, Wirtschaftsforschung DIf (2012) Messartefakte bei der Erfassung der Gesundheit von Migranten in Deutschland: zur interkulturellen Äquivalenz des SF-12-Fragebogen im Soziooekonomischen Panel (SOEP). SOEPpapers on Multidisciplinary Panel Data Research at DIW Berlin; 447. DIW Berlin, Berlin
- 40. Smith AW, Bellizzi KM, Keegan TH, Zebrack B, Chen VW, Neale AV, Hamilton AS, Shnorhavorian M, Lynch CF (2013) Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience study. J Clin Oncol 31 (17):2136-2145. doi:10.1200/JCO.2012.47.3173
- 41. Lätsch D, Pfiffner, R., Wild-Näf, M. (2011) Die Gesundheit sozialhilfebeziehender Erwerbsloser in der Stadt Bern. Schlussbericht zuhanden des Auftraggebers.